Johnson & Johnson (JNJ) Lifted to “Buy” at Vetr Inc.
Vetr upgraded shares of Johnson & Johnson (NYSE:JNJ) from a hold rating to a buy rating in a research note issued to investors on Tuesday morning. Vetr currently has $123.13 target price on the stock.
A number of other equities analysts also recently weighed in on the stock. Zacks Investment Research downgraded shares of Johnson & Johnson from a buy rating to a hold rating in a report on Tuesday, September 20th. Credit Suisse Group AG reissued a neutral rating and issued a $123.00 price target on shares of Johnson & Johnson in a report on Monday, September 19th. Jefferies Group cut their price target on shares of Johnson & Johnson from $119.00 to $115.00 and set a hold rating on the stock in a report on Tuesday, September 13th. Leerink Swann reissued a buy rating on shares of Johnson & Johnson in a report on Sunday, September 11th. Finally, BTIG Research reissued a neutral rating on shares of Johnson & Johnson in a report on Wednesday, September 7th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and eleven have assigned a buy rating to the stock. The company has an average rating of Hold and a consensus target price of $120.19.
Johnson & Johnson (NYSE:JNJ) opened at 117.27 on Tuesday. The company has a market capitalization of $320.84 billion, a price-to-earnings ratio of 21.85 and a beta of 0.61. The firm has a 50-day moving average of $119.39 and a 200 day moving average of $116.58. Johnson & Johnson has a 12-month low of $91.84 and a 12-month high of $126.07.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, July 19th. The company reported $1.74 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.68 by $0.06. The company had revenue of $18.50 billion for the quarter, compared to the consensus estimate of $17.98 billion. Johnson & Johnson had a net margin of 20.97% and a return on equity of 24.70%. Analysts expect that Johnson & Johnson will post $6.69 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd were paid a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a dividend yield of 2.73%. The ex-dividend date of this dividend was Friday, August 19th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 60.15%.
In other news, CAO Ronald A. Kapusta sold 2,935 shares of the stock in a transaction that occurred on Friday, July 22nd. The stock was sold at an average price of $125.01, for a total transaction of $366,904.35. Following the completion of the sale, the chief accounting officer now owns 28,660 shares of the company’s stock, valued at $3,582,786.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Dominic J. Caruso sold 41,146 shares of the stock in a transaction that occurred on Tuesday, July 26th. The shares were sold at an average price of $125.01, for a total value of $5,143,661.46. Following the sale, the vice president now directly owns 157,819 shares of the company’s stock, valued at approximately $19,728,953.19. The disclosure for this sale can be found here. Insiders own 0.11% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the stock. Americafirst Capital Management LLC bought a new stake in Johnson & Johnson during the second quarter worth $101,000. Tuttle Tactical Management LLC bought a new stake in Johnson & Johnson during the second quarter worth $103,000. Lenox Wealth Management Inc. raised its stake in Johnson & Johnson by 24.3% in the second quarter. Lenox Wealth Management Inc. now owns 972 shares of the company’s stock worth $118,000 after buying an additional 190 shares during the period. Thomas J. Herzfeld Advisors Inc. raised its stake in Johnson & Johnson by 221.2% in the second quarter. Thomas J. Herzfeld Advisors Inc. now owns 1,002 shares of the company’s stock worth $122,000 after buying an additional 690 shares during the period. Finally, NCM Capital Management Group Inc. bought a new stake in Johnson & Johnson during the second quarter worth $127,000. 65.32% of the stock is owned by hedge funds and other institutional investors.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.